Phase 3
Biogen reported new data from a long-term extension phase of the Phase III clinical studies of Aduhelm (aducanumab) for Alzheimer’s disease.
A checkpoint inhibitor under development by China’s Junshi Biosciences and Coherus BioSciences hit the mark in a Phase III lung cancer study.
After the announcement, Nektar shares dropped 36%, going from $6.47 per share to $4.16.
The investigational oral drug for vasomotor symptoms in menopause women couldn’t meet the pre-defined efficacy. Here’s how it performed during the clinical stages.
Incyte Corporation reported that the FDA has pushed back the review of the company’s supplemental New Drug Application (sNDA) for Opzelura (ruxolitinib cream) for vitiligo.
In the latest results shared by the company, treatment with nusinersen for a median of 4.9 years helped participants maintain and make progressive gains in motor function.
The U.S. FDA has approved Lynparza for the adjuvant treatment of patients diagnosed with germline BRCA-mutated HER2-negative high-risk early breast cancer.
Novartis released new data Monday from its Phase III SPR1NT trial that reinforces the benefits of Zolgensma.
This week is starting off strong with some positive clinical news from Ascendis Pharma, Can-Fite and BridgeBio.
AstraZeneca’s Fasenra hit a roadblock after the FDA issued a Complete Response Letter for chronic rhinosinusitis with nasal polyps (CRSwNP).
PRESS RELEASES